Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|June 13, 2022

Dr. Lotan on the iodine-based contrast media shortage

Author(s)Urology Times staff

“For patients who are several years out from treatment for bladder cancer or kidney cancer, I don't think [the shortage is] going to have a clinical impact. For more acute settings, I have tried to rely a little bit more on MR urograms and ultrasound,” says Yair Lotan, MD.

In this interview, Yair Lotan, MD, is a professor of urology, chief of Urologic Oncology, the Jane and John Justin Distinguished Chair in Urology, in honor of Claus G. Roehrborn, MD, and vice chair of clinical affairs at the University of Texas Southwestern Medical Center in Dallas.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure

ByNicole L. Miller, MD, FACS

June 9th 2026

Study suggests potential diuretic effect with nadofaragene firadenovec

ByAbigail Keller, MD

June 8th 2026

Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC

ByPraful Ravi, MB, BChir, MRCP

June 4th 2026

Pedro Barata, MD, highlights phase 3 data on 177Lu-rosopatamab tetraxetan in mCRPC

ByPedro Barata, MD, MSc, FACP

June 2nd 2026

Tanya B. Dorff, MD, highlights early data on ABBV-969 in mCRPC

ByTanya B. Dorff, MD, FASCO

June 1st 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Trending on Urology Times

Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer

Study suggests potential diuretic effect with nadofaragene firadenovec

The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD

Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure

Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026